CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2026 Jul 18, 05:18

BioNTech (NASDAQ:BNTX) Upgraded to Hold at Wall Street Zen

BioNTech SE
Webhose 2026 Jul 18, 01:23

How Investors Are Reacting To BioNTech (BNTX) Expanded Global Patent Suits Targeting Its mRNA COVID-19 Vaccines

BioNTech SE
Webhose 2026 Jul 16, 13:07

Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech - Update | Morningstar

BioNTech SE
Webhose 2026 Jul 16, 00:00

BioNTech comes to Jerusalem: Mayor Moshe Lion announces new mRNA vaccine center

BioNTech SE
Webhose 2026 Jul 15, 00:00

Pfizer vaccine generates strong immune response in children under 5

BioNTech SE
Webhose 2026 Jul 15, 00:00

Pfizer says vaccine is 100% effective in protecting adolescents

BioNTech SE
Webhose 2026 Jul 11, 13:36

Candriam S.C.A. Lowers Holdings in BioNTech SE Sponsored ADR $BNTX

BioNTech SE
Webhose 2026 Jul 11, 06:25

BioNTech (BNTX) Could Be 82% Undervalued On Its Manufacturing Reset

BioNTech SE
Webhose 2026 Jul 10, 12:15

BioNTech (BNTX) Stock Could Be Overvalued After a 58% Five Year Slump

BioNTech SE
Webhose 2026 Jul 10, 07:35

Hsbc Holdings PLC Makes New $4.97 Million Investment in BioNTech SE Sponsored ADR $BNTX - Markets Daily

BioNTech SE
Webhose 2026 Jul 09, 04:05

Cathie Wood Buys More SpaceX, Sells AMD, BioNTech, and Other Growth Stocks, 7/9/26

BioNTech SE
Webhose 2026 Jul 08, 14:33

BioNTech and Pfizer secure big European win over mRNA patent

BioNTech SE
Webhose 2026 Jul 06, 14:34

10 Newly Overvalued Stocks this Week | Morningstar

BioNTech SE
Webhose 2026 Jul 05, 05:28

BioNTech (BNTX) Is Up 6.9% After Moving To Exit German Manufacturing Sites Has The Bull Case Changed?

BioNTech SE
Webhose 2026 Jul 04, 08:48

Pictet Asset Management Holding SA Boosts Stake in BioNTech SE Sponsored ADR $BNTX

BioNTech SE
Webhose 2026 Jul 03, 11:29

BioNTech in Talks to Sell German Sites Amid Planned Closures, ETPharma

BioNTech SE
Webhose 2026 Jul 02, 00:00

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

BioNTech SE
Webhose 2026 Jul 01, 09:45

mRNA Cancer Vaccine Market to Surpass $1.20 Billion in 2026 as Personalized Oncology Immunotherapies Advance, New Report Finds

BioNTech SE
Webhose 2026 Jun 30, 00:00

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer

BioNTech SE
Webhose 2026 Jun 28, 08:24

52,279 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Hsbc Holdings PLC

BioNTech SE
Webhose 2026 Jun 26, 20:22

BioNTech (BNTX) And The AI Cancer Narrative Behind Its Undervalued View

BioNTech SE
Webhose 2026 Jun 25, 08:40

SG Americas Securities LLC Sells 95,088 Shares of BioNTech SE Sponsored ADR $BNTX

BioNTech SE
Webhose 2026 Jun 22, 10:35

Virtu Financial LLC Has $1.07 Million Stake in BioNTech SE Sponsored ADR $BNTX - Markets Daily

BioNTech SE
Webhose 2026 Jun 22, 06:34

Virtu Financial LLC Has $1.07 Million Stock Position in BioNTech SE Sponsored ADR $BNTX - Stock Observer

BioNTech SE

BioNTech news

Latest news

Info

Spread

0.6796

Spread (%)

0.7446 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

13:31 - 19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

23133851648

Shares Outstanding

252884261

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-5.77

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now

Latest Education Articles

Trustpilot